Katarina Luptakova - 05 Sep 2023 Form 4 Insider Report for Xilio Therapeutics, Inc. (XLO)

Role
Chief Medical Officer
Signature
/s/ Julia Walcott, Attorney-in-Fact
Issuer symbol
XLO
Transactions as of
05 Sep 2023
Net transactions value
$0
Form type
4
Filing time
07 Sep 2023, 16:26:08 UTC
Next filing
03 Jan 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XLO Stock Option (Right to Buy) Award $0 +106,000 $0.000000 106,000 05 Sep 2023 Common Stock 106,000 $2.79 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option was granted on September 5, 2023 and will vest in equal monthly installments beginning on October 1, 2023 through September 1, 2027.